1) Its products are mainly over the counter (OTC), Therapeutic and prescription drugs. It sells over to 60+ countries. They have received awards for National Award for Outstanding Entrepreneurship for medium enterprise, National Award for Research and development Efforts, Outstanding export performance of formulations award by PHARMEXCIL for small scale category of india.

2) It has inaugurated a new plant in palghar, with this it has become the largest manufacturers of suppositories and pessaries in india and amongst the largest in the world. It has also done some strategic acquisitions to enter into ointment sector also it has bought stakes in sales packaging services which will help in reducing their packaging cost significantly by acquisitions. It also started BLISS GVS Healthcare ltd in Nigeria a medical center.

3) It has shown a consistent growth in bookvalue also it has good growth in EPS too.

4) Its antimalarial drug lonart is the flagship product(even fake product has come in blackmarket because of its popularity).It also has a product in female contraceptive product known as TODAY is somewhat known. BRANDED GENERICS IN ANTI FUNGAL sector huge potential in Africa. Medicines through picking tenders in Africa WHO.

5) THE ATTRACTIVE THING IS IT’S A ZERO DEBT COMPANY.6) Good OPM and NPM, Promoter holdings is 64% which shows the

confidence in the company by the promoters, ASSET LIGHT BUSINESS, Consistent dividend paying company

7) Couldn’t find any bad news regarding the company ,there was an issue Ghana but it was cleared by the management.They have good supply chain in the African market. It has placed itself strategically into less driven markets with malaria concentration of 80 %.

8) The MD has a service experience of 2 decades in African countries.

9) The trends in pessary usage has declined overall with the introduction of surgery, people who avoids surgery will continue using pessary mostly in 3rd world countries where the compay is focused.Analysed with buffet and rohith Chauhan tool couldn’t find anything bad.

10)The PE ratio looks fine for a pharma company.The EPS CAGR for past 9 years stand at 14%,wheras for the past 6 years it only stands at 7.87%.This gives a PEG of 1.73 for the past 6 years(here it appears on the higher side and shows the stock is expensivebased on this ratio, but I think they have spend money upon proper capital expenditure and strategic acquisitions to stay on the niche field.) and a PEG of 1 for the last 10 year

11) Their ROE is quite good but they have opened a new plant since its an asset light business will it get more sales thereby increasing value for the shareholders I hope,

NEGATIVES

1) The earnings growth has not shown consistency also its last 6 years earning growth is 7.87% and the 9-year earning growth is a also not so bright 14% .(SCALABLE BUSINESS AND EARNING GROWTH IS WHAT A MARKET PAYS FOR ATLAST).

2) Despite of the fact and considering the bull run the company has had a run already and is evaluated at a 13.7 PE for a interest in earning of 14.7% over a CAGR-9YR and 7.87% over a CAGR-4YR,SO its terribly overvalued.(Really I should not have bought the stock in the first place, based on this it looks stupid.)

3) The Earnings from the new plants are not shown in the sales growth since its production has just begun after this march.If the financial reports are poor book the loss and get out of the stock.

4) The ROCE is also declining.(-ve)5) The Number of outstanding shares is 10 crores.